TC BioPharm (Holdings) Ltd - TCBP STOCK NEWS

TC BioPharm (TCBP) has announced the completion of Cohort A dosing in its ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 for acute myeloid leukemia (AML) and myelodysplastic syndromes. The preliminary results show promising outcomes with no drug-related adverse events and evidence of stable disease in several patients following multiple TCB008 infusions.

Cohort A, which was re-initiated in July 2024, targeted patients ineligible for or who had exhausted all available therapies. The trial utilized higher doses of TCB008, containing up to a billion Gamma Delta T-Cells. While Cohort A enrollment has concluded, recruitment for Cohort B continues. The company reports expedited data delivery, occurring just six months after study re-initiation.

TC BioPharm (TCBP) announced successful completion of initial Cohort B patient dosing in the ACHIEVE Phase 2B clinical trial, evaluating TCB008 for Acute Myeloid Leukemia (AML). The first Cohort B patient received all four planned doses, totaling approximately 819 million Gamma Delta T-cells, with a fifth dose expected.

The ACHIEVE trial, an open-label Phase II study, evaluates TCB008's efficacy and safety in patients with AML and myelodysplastic syndromes (MDS/AML). Cohort B specifically targets patients in remission but with detectable minimal residual disease (MRD). Recruitment began in Q4 2024, ahead of schedule, with the first patient dosed in October 2024.

Preliminary data shows no drug-related adverse events following cumulative infusions of up to a billion cells, supporting TCB008's positive safety profile. The company expects to complete Cohort B enrollment in H1 2025, with data readout anticipated later in the year.

TC BioPharm (NASDAQ: TCBP) announced a significant change in its American Depositary Shares (ADS) ratio, effective February 10, 2025. The ratio will shift from 1 ADS representing 200 ordinary shares to 1 ADS representing 4,000 ordinary shares. This adjustment effectively implements a 1-for-20 reverse ADS split.

The change requires ADS holders to exchange every 20 ADSs for 1 new ADS, with The Bank of New York Mellon managing the exchange process. No ordinary shares will be issued or canceled, and TCBP will continue trading on Nasdaq Capital Market. Fractional new ADSs will be aggregated and sold, with net proceeds distributed to affected holders.

While the ADS trading price is expected to increase proportionally, the company provides no guarantees regarding the post-change trading price relationship.

TC BioPharm (NASDAQ: TCBP) announced plans to initiate Proof of Concept preclinical studies for its lead therapeutic TCB008 to treat H5N1 (Bird Flu). The company is seeking university partnerships to accelerate preclinical work needed for Phase I studies. TCB008 is an allogeneic, unmodified cell therapy composed of activated and expanded gamma delta T cells, which the company believes could help address the emerging avian bird flu epidemic.

The announcement follows the first reported U.S. death from H5N1 by the Louisiana Department of Health. H5N1 is a viral infection typically contracted through contact with infected birds but can spread between humans, with symptoms appearing within 2-8 days, resembling common flu symptoms and potentially carrying high mortality rates in humans.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other conditions, has announced its participation in the upcoming Sequire Investor Summit 2025. The company's CEO, Bryan Kobel, will deliver a corporate overview presentation at the event, which is scheduled for January 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other conditions, has announced the continuous trading of its American Depository Shares (ADSs) on the Nasdaq Global Select Market under the ticker symbol 'TCBP'. The company confirmed there has been no interruption in trading, and shares are expected to continue trading without disruption.

TC BioPharm (NASDAQ: TCBP) has advanced negotiations with previously announced acquisition candidates as part of its M&A expansion strategy. The company is focusing on two main areas: Natural Kill cell technologies and CAR-related technologies.

TCBP is prioritizing near-term opportunities in the NK space, exploring allogeneic NK and CAR-NK technologies to expand into autoimmune disease, solid tumors, and combination therapies with TCB008. The company is also pursuing novel CAR technologies to enhance TCB008's efficacy in solid tumors and other cancers, aiming to increase therapeutic use cases and manufacturing site utilization.

Management reports positive progress in discussions with current acquisition targets, focusing on companies with proprietary treatment approaches that complement TCBP's platform.

TC BioPharm (NASDAQ: TCBP) announced shareholders' approval of a 25% stock dividend. Shareholders will receive 0.25 American Depositary Shares (ADSs) for every 1 ADS held as of January 2, 2025, with delivery expected around January 6th. Trading will temporarily halt from January 2, 2025, at 5:00 pm and resume around January 8, 2025, to process the dividend. Nasdaq will adjust the opening price on January 8 to reflect dilution impact.

CEO Bryan Kobel stated this special dividend reflects management's confidence in the company's financial future and is part of their capital management strategy. He anticipates 2025 to be a period of growth and development, focusing on delivering improved shareholder value.

TC BioPharm (NASDAQ: TCBP) has announced and received shareholder approval for a 25% stock dividend. Shareholders will receive 0.25 American Depositary Shares (ADSs) for every 1 ADS held as of the record date of January 2, 2025. The distribution is expected to occur on or about January 6th, 2025.

Trading of TCBP's ADSs will temporarily halt at 5:00 pm on January 2, 2025, and resume on January 7, 2025, allowing the Depositary to process the stock dividend. Nasdaq will adjust the opening price on January 7 to account for the dilution impact.

CEO Bryan Kobel emphasized that this special dividend demonstrates management's confidence in the company's financial future and serves as a component of their capital management strategy. He expressed optimism about 2025 being a period of growth and development for the clinical-stage biotechnology company, which develops platform allogeneic gamma-delta T cell therapies for cancer and other indications.